Hydroxychloroquine in Type 2 Diabetes During Pregnancy

Conditions studied

Diabetes in Pregnancy, Type 2 Diabetes

About this study

The goal of this clinical trial is to compare the use of hydroxychloroquine as an adjunct to the current treatment of pregnant women with Type 2 diabetes mellitus. The main questions it aims to answer are: * Does hydroxychloroquine improve the pregnancy outcomes in women with type 2 diabetes during pregnancy? * Does hydroxychloroquine improve the inflammatory markers in women with type 2 diabetes during pregnancy? Participants will be randomised into the intervention and control group. The control group will be on standard treatment where as the intervention group will receive hydroxychloroquine as an adjunct of standard treatment

Interventions

• Drug: Hydroxychloroquine Oral Tablet — 200mg daily

Primary outcomes

• To compare the serum glycated haemoglobin (HbA1c) between the two groups (From Day 1 up to 38 weeks of gestation)
• To compare the serum fructosamine between the two groups (From Day 1 up to 38 weeks of gestation)
• To compare the serum interleukin-6 between the two groups (From Day 1 up to 38 weeks of gestation)
• To compare the serum interleukin-10 between the two groups (From Day 1 up to 38 weeks of gestation)
• To compare the serum tumour necrosis factor alpha between the two groups (From Day 1 up to 38 weeks of gestation)

Eligibility information

Study locations

• Antenatal clinic, UKM Medical Centre, Cheras, Kuala Lumpur 56000 Malaysia